

**Diaceutics PLC  
("Diaceutics" or the "Group")**

**AGM Statement  
Q1 Trading Update**

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, is holding its Annual General Meeting (AGM) today at 2.00 p.m. at the registered office of the Company at 55-59 Adelaide Street, Belfast, BT2 8FE.

In normal circumstances, the Board greatly values the opportunity to meet shareholders in person. However, due to the COVID-19 pandemic and the Government's advice on non-essential travel and mandatory social distancing, shareholder attendance at the AGM is not possible, as previously communicated. The result of the poll voting on each of the resolutions to be put to the AGM will be reported via RNS later today.

**Q1 Trading Update**

Diaceutics has made a good start to the 2020 financial year and trading in the first quarter was in line with the Board's expectations. Guidance for the full year remains unchanged.

The Group continues to make excellent operational progress with its diagnostic network, called DXRX - The Diagnostic Network™, formerly known as Nexus. This unique platform will enable Diaceutics to meet the need for a global standardised diagnostic process by offering an end-to-end solution for the development and commercialisation of precision medicine diagnostic testing. It will significantly enhance Diaceutics' customer service offering to meet the increased market demand being created by new precision medicines currently in pharmaceutical company pipelines.

Diaceutics' interim results for the six months ending 30 June 2020 are expected to be announced on 7 September 2020.

**Julie Goonewardene, Chair of Diaceutics PLC, commented:** *"In light of the disruption caused by COVID-19 across the world, I'm extremely proud of the achievements of all the employees at Diaceutics and the great progress that is being made by the Group in the rollout of DXRX. This integrated platform will simplify the increasingly complex precision testing ecosystem and we look forward to its commercial launch later in the year."*

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

**Enquiries:**

**Diaceutics PLC**

Stuart Hunt, Head of Investor Relations

Tel: +44 (0)7815 778 536

**Cenkos Securities PLC (Nomad & Broker)**

Callum Davidson / Giles Balleny  
Michael Johnson (Sales)

Tel: +44(0)20 7397 8900

**Walbrook PR**

Anna Dunphy  
Paul McManus

Tel: +44 (0)20 7933 8780 or [diaceutics@walbrookpr.com](mailto:diaceutics@walbrookpr.com)

Tel: +44 (0)7876 741 001

Tel: +44 (0)7980 541 893

**About Diaceutics**

Diaceutics PLC is a diagnostic commercialisation company for the Precision Medicine industry. The Company, quoted on the AIM Market of the London Stock Exchange, is enabling pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 35 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries. [www.diaceutics.com](http://www.diaceutics.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

END

AGMFZGMKRRLLGGZM